Voyager Therapeutics (NASDAQ:VYGR) Upgraded to Hold at Wall Street Zen

Wall Street Zen upgraded shares of Voyager Therapeutics (NASDAQ:VYGR) from a sell rating to a hold rating in a research report report published on Saturday morning.

Voyager Therapeutics Trading Down 8.6%

Shares of NASDAQ VYGR opened at $4.45 on Friday. Voyager Therapeutics has a 12-month low of $2.64 and a 12-month high of $5.55. The firm’s 50-day moving average price is $3.92 and its 200-day moving average price is $4.18. The stock has a market capitalization of $265.22 million, a price-to-earnings ratio of -2.19 and a beta of 1.32.

Voyager Therapeutics (NASDAQ:VYGR) last released its quarterly earnings results on Monday, March 9th. The company reported ($0.46) EPS for the quarter, topping the consensus estimate of ($0.54) by $0.08. Voyager Therapeutics had a negative return on equity of 51.35% and a negative net margin of 296.53%.The company had revenue of $13.46 million during the quarter, compared to analyst estimates of $10.49 million. On average, equities analysts predict that Voyager Therapeutics will post -0.91 EPS for the current fiscal year.

Insider Activity at Voyager Therapeutics

In other news, CEO Alfred Sandrock sold 14,197 shares of the business’s stock in a transaction that occurred on Tuesday, February 24th. The stock was sold at an average price of $3.79, for a total transaction of $53,806.63. Following the transaction, the chief executive officer owned 484,060 shares of the company’s stock, valued at approximately $1,834,587.40. The trade was a 2.85% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In the last three months, insiders sold 49,783 shares of company stock valued at $188,694. 6.39% of the stock is currently owned by insiders.

Institutional Trading of Voyager Therapeutics

A number of institutional investors have recently bought and sold shares of VYGR. Barclays PLC boosted its stake in Voyager Therapeutics by 2.5% during the fourth quarter. Barclays PLC now owns 162,112 shares of the company’s stock worth $637,000 after buying an additional 4,003 shares during the period. Allspring Global Investments Holdings LLC raised its stake in shares of Voyager Therapeutics by 9.6% in the fourth quarter. Allspring Global Investments Holdings LLC now owns 61,775 shares of the company’s stock valued at $249,000 after acquiring an additional 5,422 shares during the period. Goldman Sachs Group Inc. raised its stake in shares of Voyager Therapeutics by 1.9% in the fourth quarter. Goldman Sachs Group Inc. now owns 303,133 shares of the company’s stock valued at $1,191,000 after acquiring an additional 5,560 shares during the period. American Century Companies Inc. lifted its holdings in shares of Voyager Therapeutics by 5.1% in the 2nd quarter. American Century Companies Inc. now owns 138,269 shares of the company’s stock worth $430,000 after acquiring an additional 6,748 shares during the last quarter. Finally, Jain Global LLC lifted its holdings in shares of Voyager Therapeutics by 44.1% in the 3rd quarter. Jain Global LLC now owns 28,104 shares of the company’s stock worth $131,000 after acquiring an additional 8,600 shares during the last quarter. 48.03% of the stock is currently owned by institutional investors.

About Voyager Therapeutics

Voyager Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of gene therapies for serious neurological diseases. The company’s core activities center on the design and delivery of engineered adeno-associated viral (AAV) vectors tailored to target cells in the brain and central nervous system. Through its proprietary CapsidMap and VectorMap platforms, Voyager aims to enhance vector potency, specificity and durability to address diseases with high unmet medical need.

The firm’s pipeline includes several AAV-based candidates in preclinical and early clinical development.